TipRanks on MSN

Biogen price target raised to $153 from $135 at Citi

Citi raised the firm’s price target on Biogen (BIIB) to $153 from $135 and keeps a Neutral rating on the shares. The firm adjusted price targets ...

Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying ...

Based on Stoke Therapeutics’ preliminary estimates, which scaled annual incidence to prevalence using country-specific live birth rates over the past 85 years and adjusted for Dravet-specific ...